Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation

References

• Mitsani D, Neofytos D. Changing epidemiology of invasive fungal infections in hematopoitic stem cell transplantation. J. Invasive Fungal Infect.3(4), 123–130 (2010).
   Google Scholar
• Singh N. Impact of current transplantation on the changing epidemiology of infections in transplant recipients. Lancet Infect. Dis.3, 156–161 (2003).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant.9, 801–808 (1997).
   Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100, 4358–4366 (2002).
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneicperipheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br. J. Haematol.116, 475–482 (2002).
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik J, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis.175, 1459–1466 (1997).
   PubMed Web of Science ®Google Scholar
• Baddley JW, Stroud TP, Dalzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis.32, 1319–1324 (2001).
   PubMed Web of Science ®Google Scholar
• Grow WB, Moreb JS, Roque D et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant.29, 15–19 (2002).
   PubMed Web of Science ®Google Scholar
• Jantunen E, Salonen J, Juvonen E et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur. J. Haematol.73, 174–178 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Paterson D, Singh N. Invasive aspergillosis in transplant recipients. Medicine78, 123–138 (1999).
   PubMed Web of Science ®Google Scholar
• Montoya JG, Giraldo LF, Efron B et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin. Infect. Dis.33, 629–640 (2001).
   PubMed Web of Science ®Google Scholar
• Minari A, Husni R, Avery RK et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl. Infect. Dis.4, 195–200 (2002).
   PubMedGoogle Scholar
• Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J. Heart Lung Transplant.22, 258–266 (2003).
   PubMed Web of Science ®Google Scholar
• Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis.36, 46–52 (2003).
   PubMed Web of Science ®Google Scholar
• Montoya JG, Chaparro SV, Celis D et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin. Infect. Dis.37(Suppl. 3), S281–S292 (2003).
   Google Scholar
• Patterson TF. Advances and challenges in the management of invasive mycoses. Lancet366, 1013–1025 (2005).
   PubMed Web of Science ®Google Scholar
• De La Rose GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogenic blood and marrow transplant recipients. Transplant Infect. Dis.4, 3–9 (2003).
   Google Scholar
• Garcia-Vidal C, Uptor A, Kirby KA et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin. Infect. Dis.47, 1041–1050 (2008).
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, Sandmaier BH, Maris HB, Maloneyl DG. Risk and outcomes of invasive fungal infections in recipients of allogeneic hematopoetic stem cell transplants after nonmyeloablative conditioning. Blood102, 827–833 (2003).
   PubMed Web of Science ®Google Scholar
• Labne AC, Su SH, Laverdiere M et al. High incidence of invasive aspergillosis associated with intentinal graft-versus-host disease following nonmyeloablative transplantation. Biol. Blood Marrow Transplant.13, 1192–1200 (2007).
   PubMedGoogle Scholar
• Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoetic stem cell transplant recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis.50, 1091–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Seo KW, Kim DH, Sohn SK et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonory aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant.36, 1089–1095 (2005).
   PubMed Web of Science ®Google Scholar
• Bochud PV, Chien JW, Marr KA et al. Toll-like receptor 4 polymorphisms and aspergillesis in stem-cell transplantation. N. Engl. J. Med.359, 1766–1777 (2008).
   PubMed Web of Science ®Google Scholar
• Kesh S, Mensah NY, Peterlongo P et al. TLR1 and TLR6 polymorphisms are assocciated with susceptibility to invasive aspergillosis after allogeneic stem cell transplation. Ann. NY Acad. Sci.1062, 95–103 (2005).
   PubMed Web of Science ®Google Scholar
• Pappas P, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis.50, 1101–1111 (2010).
   PubMed Web of Science ®Google Scholar
• Fortun JP, Martin-Davila P, Morono S et al. Risk factors for invasive aspergillosis in liver transplant recipient. Liver Transplant.8, 1065–1070 (2002).
   PubMed Web of Science ®Google Scholar
• Sing N, Heitman J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation77, 795–800 (2004).
   PubMedGoogle Scholar
• Mehrad B, Paciocco G, Martinez FJ et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest119, 169–175 (2001).
   PubMed Web of Science ®Google Scholar
• Sing N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. Heart Lung Transplant.21, 258–266 (2003).
   Google Scholar
• Speziali G, McDougall JC, Midthun DE et al. Native lung complications after single lung transplantation for emphysema. Transplant. Int.10, 113–115 (1997).
   PubMedGoogle Scholar
• Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin. Microbial. Rev.18, 44–69 (2005).
   PubMed Web of Science ®Google Scholar
• Munoz P, Alcala L, Sanchez Conde M et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation75, 326–329 (2003).
   PubMed Web of Science ®Google Scholar
• Montoya JG, Chaparro SV, Celis D et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin. Infect. Dis.37, S281–S292 (2003).
   Google Scholar
• Munoz P, Rodriguez C, Bouza E, Palonro J, Yanoz J Dominguez MJ; DESCOM. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral inraconazole prophylaxis. Am. J. Transplant.4, 636–643 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen J, Guinea J, Torres-Narbona M et al. Post-surgical invasive aspergillosis: an uncommon and under-appreciated entitiy. J. Infect.60, 162–167 (2010).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine78, 123–138 (1999).
   PubMed Web of Science ®Google Scholar
• Fortun JP, Martin-Davila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transplant.8, 1065–1070 (2002).
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infections in adult hematopoetic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis.48, 265–273 (2009).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Kontoyiannis DP et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis.39, 192–198 (2004).
   PubMed Web of Science ®Google Scholar
• Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp nov, a new sibling species of A. fumigatus. Eukaryot. Cell4, 625–632 (2005).
   PubMedGoogle Scholar
• Panackal AA, Imhof A, Hanley EW, Marr KA. Aspergillus ustus infections among transplant recipients. Emerg. Infect. Dis.12, 403–408 (2006).
   PubMed Web of Science ®Google Scholar
• Alhambra A, Catalan M, Moragues MD et al. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev. Iberoam. Micol.25(4), 246–249 (2008).
   PubMedGoogle Scholar
• Jantunen E, Piilonen A, Volin L et al. Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant.25, 867–871 (2000).
   PubMed Web of Science ®Google Scholar
• Maertens JJ, Verhaegan J, Demuynck H et al. Autopsycontrolled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillsois. J. Clin. Microbiol.37, 3223–3228 (1999).
   PubMed Web of Science ®Google Scholar
• Stynen D, Goris A, Sarfati J, Latgé JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J. Clin. Microbiol.33, 497–500 (1995).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46, 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas L, Baggen L, Chisholm J et al. Diagnosis and treatment of aspergillosis in children. Expert Rev. Anti Infect. Ther.7, 461–472 (2009).
   PubMed Web of Science ®Google Scholar
• Verdaguer V, Walsh TJ, Hope W et al. Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Rev. Mol. Diagn.7, 21–32 (2007).
   PubMed Web of Science ®Google Scholar
• Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin. Chest Med.30, 367–377 (2009).
   PubMed Web of Science ®Google Scholar
• Adam O, Auperin A, Wilquin F et al. Treatment with piperacillin–tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin. Infect. Dis.38, 917–920 (2004).
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Metan G, Altun B, Hascelik G, Uzun O. False positivity for Aspergillus antigenemia related to the administration of piperacillin/tazobactam. Eur. J. Intern. Med.16(7), 489–491 (2005).
   PubMedGoogle Scholar
• Steinbach WJ. Invasive aspergillosis in pediatric patients. Curr. Med. Res. Opin.26(7), 1779–1787 (2010).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol.20, 1898–1906 (2002).
   PubMed Web of Science ®Google Scholar
• Sulahian A, Boutboul F, Ribaud P et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer91, 311–318 (2001).
   PubMed Web of Science ®Google Scholar
• Ulusakarya A, Chachaty E, Vantelon JM et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol. J.1, 111–116 (2000).
   PubMedGoogle Scholar
• Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood97, 1604–1610 (2001).
   PubMed Web of Science ®Google Scholar
• Bretagne S, Costa JM, Bart-Delabesse E et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin. Infect. Dis.26, 1407–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Machetti M, Feasi M, Mordini N et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant.21, 917–921 (1998).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation – focus on aspergillosis. Clin. Chest Med.30, 295–306 (2009).
   PubMed Web of Science ®Google Scholar
• Segal BH. Aspergillosis. N. Engl. J. Med.360, 1870–1884 (2009).
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol.19, 253–259 (2001).
   PubMed Web of Science ®Google Scholar
• Abramson S. The air crescent sign. Radiology218, 230–232 (2001).
   PubMed Web of Science ®Google Scholar
• Carvalho-Dias VM, Sola CB, Cunha CA, Shimakura SE, Pasquini R, Queiroz-Telles F. Invasive aspergillosis in hematopoietic stem cell transplant recipients: a retrospective analysis. Braz. J. Infect. Dis.12(5), 385–389 (2008).
   PubMedGoogle Scholar
• Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin. Infect. Dis.44(3), 373–379 (2007).
   PubMed Web of Science ®Google Scholar
• Park SY, Lee SO, Choi SH et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J. Infect.61(6), 492–498 (2010).
   PubMed Web of Science ®Google Scholar
• Karthaus M. Guideline based treatment of invasive aspergillosis. Mycoses53, 36–43 (2010).
   PubMedGoogle Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother.48, 2166–2172 (2004).
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics121, e1286–e1294 (2008).
   PubMed Web of Science ®Google Scholar
• Infectious Disases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO); Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients recommendations of the AGIHO of the DGHO. Ann. Hematol.88, 97–110 (2009).
   PubMed Web of Science ®Google Scholar
• Schwartz S, Thiel E. Cerebral aspergillosis: tissue penetration is the key. Med. Mycol.47, S387–S393 (2009).
   PubMed Web of Science ®Google Scholar
• Graybil JR. The echinocandins, first novel class of antifungals in two decades. Int. J. Clin. Pract.55, 633–638 (2001).
   PubMedGoogle Scholar
• Tawara S, Ikeda F, Maki K et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother.44, 57–62 (2000).
   PubMed Web of Science ®Google Scholar
• Kohno S, Masaoka T, Yamaguchi H. A multicenter, open-label clinical study of FK463 in patiens with deep mycoses in Japan. In: Program and Abstracts of the 42st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December 2001 (Abstract J-834).
   Google Scholar
• Ratanatharathorn V, Flynn P, Van Burik JA et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. In: Program and Abstracts of the American Society of Hematology 44th Annual Meeting. Philadelphia, Washington, DC, USA, 6–10 December 2002 (Abstract 2472).
   Google Scholar
• Van Burik J, Ratanatharathorn V, Lipton J et al. Randomized,double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant, NIAID/BAMSG protocol 46. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 27–30 September 2002 (Abstract 2503).
   Google Scholar
• Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of micafungin in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother.49, 3317–3324 (2005).
   PubMed Web of Science ®Google Scholar
• Benjamin DKJ, Driscoll T, Siebel NL et al. Safety and pharmatokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother.50, 632–638 (2006).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Mousset S, Sorensen J et al. Current practice of antifungal prophylaxis and treatment in immunocompromised children and adults with malignancies: a single centre approach. Mycoses52, 107–117 (2009).
   PubMed Web of Science ®Google Scholar
• Grigull L, Kuehlke O, Beilken A et al. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipents. Pediatr. Transplant.11, 261–266 (2007).
   PubMedGoogle Scholar
• Heykants J, Van de Valde V, Van Roor P. The clinical pharmocokinetics of itraconazole: an overview. Mycoses32, 67–87 (1989).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation74, 688–695 (2002).
   PubMed Web of Science ®Google Scholar
• Courtney R, Sansone A, Smith W et al. Posaconazole pharmacokinetics, safety and tolerebility in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol.45, 185–192 (2005).
   PubMed Web of Science ®Google Scholar
• Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother.47, 2788–2795 (2003).
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwasnski E et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in the healty adults. Br J. Clin. Pharmacol.57, 218–222 (2004).
   PubMed Web of Science ®Google Scholar
• Marchetti O, Cordonnier C, Calandra T. Empirical Antifungal Therapy 2009 Update of ECIL-1/ECIL-2 Guidelines. Presented at: 3rd European Conference on Infections in Leukemia. Juan-les-Pins, France, 25–26 September 2009.
   Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case–fatality rate: systematic review of the literature. Clin. Infect. Dis.32, 358–366 (2001).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Walsh TJ. Mycosis in pediatric patients. Infect. Dis. Clin. North Am.20, 663–678 (2006).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med. Mycology44, 163–172 (2006).
   PubMed Web of Science ®Google Scholar